

## PUBLIC SUMMARY DOCUMENT

**Product:** Moderna Flex Convex Urostomy

**Applicant:** Hollister

**Date of SPAP Meeting:** 11 April 2016

### 1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Hollister, sought listing of the Moderna Flex Urostomy One-Piece pouch with Convex Baseplate (upgraded design), in subgroup 3(b) of the Stoma Appliance Scheme (SAS) Schedule. The product, including 14 variants, was proposed at the unit price of \$6.373 with a maximum monthly quantity of 30 units.

### 2. Comparator

The applicant nominated the Moderna Flex with shallow convexity (SAS code 9803Y) from its own range, which is currently listed in subgroup 3(b), as the comparator. This product is currently listed at the unit price of \$6.373 with a maximum monthly quantity of 30 units.

### 3. Background

This was the Stoma Product Assessment Panel (SPAP)'s first consideration of this product.

### 4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a one-piece urostomy pouch with convex baseplate. The product is a direct substitute for the comparator currently available in subgroup 3(b).

### 5. SPAP Comment

#### *Clinical Analysis*

The Panel noted that the proposed product is claimed to be an upgraded version of the Moderna Flex (SAS code 9803Y) which is stated to include a curved pouch design, multiple built-in-chambers to evenly distribute urine resulting in a lower profile chamber, new valve/drain tap control function and new drainage adapter for easier connection to the pouch.

#### *Economic Analysis*

Not undertaken.

#### *Financial Analysis*

Listing of this product would be on a cost-minimisation basis compared with the nominated comparator product in subgroup 3(b) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

### 6. SPAP Recommendation

The SPAP recommended that the Moderna Flex Convex Urostomy, including 14 variants, be listed in subgroup 3(b) of the SAS Schedule at the benchmark unit price \$6.373, with a maximum monthly quantity of 30 units.

### 7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the

SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

**8. Applicant's Comment**

Hollister agrees with SPAP's recommendation.